COPD and Bronchodilators
Links shared publicly online about this topic
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
novartis.com — “FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD” View full resource at novartis.com
Most Recently Shared on March 9, 2011 at 2:40 pm By:
eyeonfda Pharma and Health Lawyer
FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD - http://ow.ly/4aQ4K
FDA Approves Once-Daily Bronchodilator for COPD - QualityPoint Technologies
qualitypointtech.net — “As a once-a-day drug, the new long-acting beta2-adrenergic agonist promises greater patient adherence than twice-daily LABAs. Medscape Medical News” View full resource at qualitypointtech.net
Most Recently Shared on July 2, 2011 at 12:45 am By:
FDA Approves Once-Daily Bronchodilator for COPD: As a once-a-day drug, the new long-acting beta2-adrenergic agonis... http://bit.ly/kUOvxK
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
novartis.com — “Basel, December 3, 2009 - Novartis announced today that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).” View full resource at novartis.com
Most Recently Shared on December 3, 2009 at 1:40 pm By:
eyeonfda Pharma and Health Lawyer
Novartis gets EU approval for new COPD treatment - http://ow.ly/Ias3
FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD
novartis.com — “FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD” View full resource at novartis.com
Most Recently Shared on March 23, 2011 at 3:24 pm By:
eyeonfda Pharma and Health Lawyer
#FDA extends regulatory review period for Novartis #COPD drug http://ow.ly/4kMob
Phase III data show Novartis investigational bronchodilator QAB149 significantly improves lung function over current treatments in COPD[1],[2]
novartis.com — “Basel, May 21, 2009 - Initial results from three pivotal phase III trials show the Novartis investigational bronchodilator QAB149 (indacaterol) could deliver clinically relevant* lung function improvements, within five minutes of the first dose, lasting for 24 hours in patients with chronic obstructive pulmonary disease (COPD)[3],[4],[5].” View full resource at novartis.com
Most Recently Shared on May 21, 2009 at 5:37 am By:
Phase III data show Novartis investigational bronchodilator QAB149 significantly improves lung function over cur.. http://twurl.nl/456hie
Nursing Medical News about Administration, Inhalation Bronchodilator Agents Pulmonary Disease, Chronic Obstructive Adrenal Cortex Hormones
mdlinx.com — “Mono- and Combination Therapy of Long-Acting Bronchodilators and Inhaled Corticosteroids in Advanced COPD” View full resource at mdlinx.com
Most Recently Shared on May 30, 2010 at 7:08 am By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Mono- and Combination Therapy of Long-Acting Bronchodilators and Inhaled Corticosteroids in Advanced COPD:... http://bit.ly/ad1ajQ #Nursing
Promising Results Of Roflumilast Treatment For Some Patients With COPD
medicalnewstoday.com — “Two articles published in this week's copd special edition of the lancet report that the drug roflumilast improves lung function and reduces exacerbations in patients with chronic obstructi” View full resource at medicalnewstoday.com
Most Recently Shared on August 28, 2009 at 10:29 am By:
Promising Results Of Roflumilast Treatment For Some Patients With COPD: Two articles published in this week's CO.. http://bit.ly/7jkh0
PharmaLive: Novartis Receives FDA Approval for Arcapta Neohaler, A Novel Once-Daily Bronchodilator for Chronic Obstructive Pulmonary Disease
pharmalive.com — “PharmaLive: Novartis Receives FDA Approval for Arcapta Neohaler, A Novel Once-Daily Bronchodilator for Chronic Obstructive Pulmonary Disease” View full resource at pharmalive.com
Most Recently Shared on July 5, 2011 at 6:20 pm By:
PharmaLive Health News and Pharma
Daily Advantage - FDA OKs Novartis COPD Bronchodilator - http://tinyurl.com/3olyl92
ingentaconnect Triple Therapy for the Management of COPD: A Review
ingentaconnect.com — “ingentaconnect Triple Therapy for the Management of COPD: A Review” View full resource at ingentaconnect.com
Most Recently Shared on June 9, 2011 at 12:26 pm By:
Juan C. Ivancevich, MD Allergist, Physician, Doctor, and Internist
COPD: There is insufficient evidence to determine if triple therapy is superior to dual bronchodilator therapy http://bit.ly/kNGfkH
Medical News: Early-Stage COPD Treatment Justified, Researchers Say - in Pulmonology, COPD from MedPage Today
medpagetoday.com — “Treatment with the long-acting inhaled bronchodilator tiotropium (Spiriva) appears to be beneficial for patients with early-stage chronic obstructive pulmonary disease, researchers found.” View full resource at medpagetoday.com
Most Recently Shared on August 28, 2009 at 3:28 pm By:
Use of long-acting bronchodilator tiotropium (Spiriva) appears to be beneficial for patients with early-stage COPD. http://bit.ly/gAysb
Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease: Indacaterol Versus Tiotropium -- Donohue et al. 182 (2): 155 -- American Journal of Respiratory and Critical Care Medicine
ajrccm.atsjournals.org — “Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Disease: Indacaterol Versus Tiotropium -- Donohue et al. 182 (2): 155 -- American Journal of Respiratory and Critical Care Medicine” View full resource at ajrccm.atsjournals.org
Most Recently Shared on July 15, 2010 at 11:05 pm By:
Michael Blaiss, MD Physician, Doctor, and Allergist
Indacaterol once daily was at least as effective as tiotropium in improving clinical outcomes for COPD http://is.gd/dtwZi
Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms
rttnews.com — “Novartis AG (NVS), Friday announced that the US Food and Drug Administration has approved once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.” View full resource at rttnews.com
Most Recently Shared on July 2, 2011 at 2:30 am By:
Michael Blaiss, MD Physician, Doctor, and Allergist
Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms, once a day bronchodilator - http://goo.gl/cd9hS
FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149... -- EAST HANOVER, N.J., March 8, 2011 /PRNewswire/ --
prnewswire.com — “FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD. - Phase III program demonstrated significant improvement in lung function lasting for 24 hours and supported safety and tolerability profile of QAB149 - COPD is a progressive and life-threatening lung” View full resource at prnewswire.com
Most Recently Shared on March 9, 2011 at 3:42 am By:
Michael Blaiss, MD Physician, Doctor, and Allergist
FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator Indacaterol http://t.co/E2ttppR
Almirall and Forest report preliminary topline results from the ACCORD COPD II Phase III study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD) - Drugs.com MedNews
drugs.com — “Barcelona and New York, October 29, 2010.- Almirall, S.A. (ALM.MC) and Forest Laboratories, Inc. (NYSE FRX) today announced top-line results from ACCORD COPD II” View full resource at drugs.com
Most Recently Shared on October 29, 2010 at 2:15 pm By:
Drugs and Devices OW OW Health
Almirall and Forest report preliminary topline results from the ACCORD COPD II Phase III study of aclidinium ... http://bit.ly/dvqUed #drug
Forest and Almirall Report Preliminary Topline Results from the ACCORD COPD II Phase III Study of aclidinium bromide in Chronic Obstructive Pulmonary Disease (COPD) - Drugs.com MedNews
drugs.com — “Oct 29, 2010 - Forest Laboratories, Inc. (NYSE FRX) and Almirall, S.A. (ALM.MC) today announced top-line results from ACCORD COPD II, a 12-week Phase III study” View full resource at drugs.com
Most Recently Shared on October 29, 2010 at 5:15 pm By:
Drugs and Devices OW OW Health
Forest and Almirall Report Preliminary Topline Results from the ACCORD COPD II Phase III Study of aclidinium ... http://bit.ly/ayMmGp #drug
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
eyeonfda
Author of the blog Eye on FDA - www.eyeonfda.com
-
MedicalFeed
Medical news and updates about medical articles and discussion in Google knols and in many medical websites.
-
eyeonfda
Author of the blog Eye on FDA - www.eyeonfda.com
Advertisement
